Journal Basic Info

  • Impact Factor: 1.995**
  • H-Index: 8
  • ISSN: 2474-1647
  • DOI: 10.25107/2474-1647
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Emergency Surgery
  •  Vascular Surgery
  •  Gastroenterological Surgery
  •  Ophthalmic Surgery
  •  Robotic Surgery
  •  Surgical Oncology
  •  Urology
  •  Bariatric Surgery

Abstract

Citation: Clin Surg. 2017;2(1):1408.Review Article | Open Access

Delineation of Inflammatory Bowel Disease by Molecular Biometrics: Verification versus Validation

Amanda D Williams and Amosy E M'Koma

Department of Microbiology and Immunology, Meharry Medical College School of Medicine, USA
Department of Biochemistry and Cancer Biology, Meharry Medical College School of Medicine, USA
Department of Surgery, Colon and Rectal Surgery, Vanderbilt University School of Medicine, USA

*Correspondance to: Amosy E M′Koma 

 PDF  Full Text DOI: 10.25107/2474-1647.1408

Abstract

Dysregulated immune responses to the gut microbiota are believed to be the driving force in the development of inflammatory bowel diseases. Even with combined modern and newer diagnostic technologies, it is difficult to accurately differentiate colonic inflammatory bowel disease, namely ulcerative colitis and Crohn’s colitis. Regardless of current advanced clinical and pathological criteria available to identify factors possible to help delineate the two entities, a subgroup of Crohn’s colitis cases are still diagnosed as ulcerative colitis. Current classification criteria as well as diagnostic modalities such as serologic, genetic and inflammatory markers fail to differentiate ulcerative colitis from Crohn’s colitis among patients with indeterminate colitis. The definitive diseases share demographic and clinical features, yet differ in tissue inflammation and damage suggesting distinct trigger and mechanisms. Since treatments differ, a biological dysregulation underlying the two forms of inflammatory bowel disease need to be elucidated in order to develop appropriate treatment strategies that achieve long-term remission and minimize risk of relapse. A molecular diagnostic tool would greatly benefit indeterminate colitis patients. Herewith, we summarize advances and explain the attempts to resolve indeterminate colitis into Crohn’s colitis and ulcerative colitis; and ascertain whether Crohn’s colitis patients mistakenly operated for definitive ulcerative colitis can molecularly be identifiable prior to surgery.

Keywords

Inflammatory bowel disease; Ulcerative colitis; Crohn’s colitis; Indeterminate colitis; de novo Crohn’s ileitis; Molecular Diagnostics; Advances and challenges

Cite the article

Williams AD, M′Koma AE. Delineation of Inflammatory Bowel Disease by Molecular Biometrics: Verification versus Validation. Clin Surg. 2017; 2: 1408.

Search Our Journal

Journal Indexed In

Articles in PubMed

Automated Sagittal Craniosynostosis Classification from CT Images Using Transfer Learning
 PubMed  PMC  PDF  Full Text
RAF Kinase Inhibitory Protein Expression and Phosphorylation Profiles in Oral Cancers
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Safely Avoiding Axillary Lymphadenectomy after Neoadjuvant Chemotherapy for Patients with Proven Axillary Lymph Node Involvement Early Breast Cancer? The French Multicenter Prospective Ongoing GANEA 3 Study
 Abstract  PDF  Full Text
Plant-Based Natural Products for Breast Cancer Prevention: A South Asian Association for Regional Cooperation (SAARC) Countries Perspective
 Abstract  PDF  Full Text
View More...